A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety, Tolerability and Activity of Intramuscularly Administered a-Epi-Br (HE2000) in Late Stage Human Immunodeficiency Virus-Infected Patients at Risk for Opportunistic Infections

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety, Tolerability and Activity of Intramuscularly Administered a-Epi-Br (HE2000) in Late Stage Human Immunodeficiency Virus-Infected Patients at Risk for Opportunistic Infections

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2009

At a glance

  • Drugs HE 2000 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors Harbor Therapeutics
  • Most Recent Events

    • 04 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top